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The self-assembly of the 42-residue amyloid-b peptide, Ab42, into fibrillar aggregates is associated with
neuronal dysfunction and toxicity in Alzheimer’s disease (AD) patient brains, suggesting that small
molecules acting on this process might interfere with pathogenesis. Here, we present experimental
evidence that the small molecule sclerotiorin (SCL), a natural product belonging to the group of azaphilones,
potently delays both seeded and nonseeded Ab42 polymerization in cell-free assays. Mechanistic
biochemical studies revealed that the inhibitory effect of SCL on fibrillogenesis is caused by its ability to
kinetically stabilize small Ab42 oligomers. These structures exhibit low b-sheet content and do not possess
seeding activity, indicating that SCL acts very early in the amyloid formation cascade before the assembly of
seeding-competent, b-sheet-rich fibrillar aggregates. Investigations with NMR WaterLOGSY experiments
confirmed the association of Ab42 assemblies with SCL in solution. Furthermore, using ion mobility-mass
spectrometry, we observed that SCL directly interacts with a small fraction of Ab42 monomers in the gas
phase. In comparison to typical amyloid fibrils, small SCL-stabilized Ab42 assemblies are inefficiently taken
up into mammalian cells and have low toxicity in cell-based assays. Overall, these mechanistic studies
support a pathological role of stable, b-sheet-rich Ab42 fibrils in AD, while structures with low b-sheet
content may be less relevant.
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Alzheimer’s disease (AD) is a late-onset neuro-
degenerative disorder characterized by memory loss
and progressive personality changes [1,2]. The self-
assembly of the 42-residue amyloid-b (Ab42) pep-
tide, produced by proteolytic cleavage of the
amyloid-b precursor protein (APP), into insoluble
fibrillar structures in AD patient brains is regarded as
one critical, possibly the key feature of pathogenesis
[3,4].thors. Published by Elsevier Ltd. This is
ses/by-nc-nd/4.0/).Various studies suggest that not only mature
amyloid fibrils but also small soluble Ab42 oligomers
lead to disease phenotypes and neuronal dysfunc-
tion [5] and cause toxicity in various cellular models
[6e8]. Whether ordered amyloid fibrils or unstruc-
tured prefibrillar oligomers are the major toxic agent
in disease, however, is still a matter of intense
debate [9].
Previous investigations with synthetic or recombi-
nant peptides have demonstrated that unstructuredan open access article under the CC BY-NC-ND license (http://
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2081Sclerotiorin Stabilizes Small Abeta42 OligomersAb42 monomers self-assemble into ordered, b-
sheet-rich amyloid fibrils by a nucleation-dependent
process [3,10] that is accelerated by the addition of
preformed amyloid fibrils, often termed “seeds” [4].
The formation of Ab42 fibrils is a complex, multistep
autocatalytic process, involving the assembly of
transient on- and off-pathway aggregate species,
whose structures, sizes, and biological activities are
not well defined [11]. Therefore, clarifying the roles of
transiently formed oligomers and other prefibrillar
structures in pathogenesis is highly relevant to
defining viable therapeutic strategies.
Several lines of experimental evidence indicate
that amyloid formation pathways can be manipulated
with chemical compounds [12], peptides [13], or
larger proteins acting as molecular chaperones [14].
Organic dyes like Congo red [15] and K114 [16] or
polyphenols like EGCG [17], which directly bind to
ordered b-sheet-rich amyloid structures, have been
shown to slow down fibrillogenesis when added to
complex Ab42 polymerization reactions. Further-
more, it was demonstrated that the chaperone
Brichos, a protein domain of ~100 amino acids that
directly binds to the surface of amyloid fibrils [18],
can efficiently inhibit the assembly of Ab42 oligo-
mers, which are formed by secondary nucleation.
Thus, small molecules or proteins that interfere with
surface-catalyzed Ab42 secondary nucleation might
have a high therapeutic potential for the treatment of
AD and other protein misfolding disorders.
If small b-sheet-rich, seeding-competent Ab42
assemblies are the major toxic species in AD, no
matter whether oligomers or fibrils, inhibition of their
formation with small molecules should reduce
toxicity. This could be achieved with chemical
compounds that preferentially target unstructured
Ab42 monomers or oligomers and prevent their
conformational conversion into b-sheet-rich, aggre-
gation-prone structures. A compound that success-
fully stabilizes the conformation of the protein
transthyretin and prevents its spontaneous misfold-
ing and aggregation has been developed for clinical
use and is now applied for the treatment of patients
of TTR amyloidosis [19,20].
Here, we searched for chemical compounds that
interfere with early events in the Ab42 aggregation
cascade and prevent the assembly of potentially
proteotoxic, b-sheet-rich structures.We identified the
natural compound sclerotiorin (SCL) and showed that
it kinetically stabilizes small nonseeding-competent
oligomerswith a low b-sheet-content, indicating that it
interferes with very early steps in the amyloid
polymerization process. NMR WaterLOGSY experi-
ments indicate that SCL interacts with newly formed
Ab42 assemblies, confirming its direct binding to the
aggregation-prone peptide. Finally, we observed that
SCL-stabilized oligomers in comparison to amyloid
fibrils are inefficiently taken up into mammalian cellsand exhibit low toxicity in cell-based assays.
Together, these studies indicate that SCL perturbs
very early events in the amyloid formation cascade
and stabilizes the assembly of benign, unstructured
Ab42 oligomers with low SDS stability. The potential
implications of these results for the treatment of AD
and other amyloid diseases are discussed.Results
The natural compound SCL potently delays both
seed-mediated and spontaneous Ab42 polymer-
ization in FP and ThT assays
We used a fluorescence polarization (FP)-based
assay to screen for small molecules that delay seed-
mediated Ab42 aggregation in vitro (fig. S1a). In this
assay, FP is used to monitor the time-dependent co-
aggregation of 5-Carboxyfluorescin-conjugated tra-
cer peptides (FAMAb42, 0.1 mM) and unlabeled Ab42
peptides (10 mM) into higher molecular weight fibrillar
structures [21]. Small, preformed, b-sheet-rich Ab42
fibrils are utilized in this method as seeds to promote
amyloid fibrillogenesis (fig. S1b). We screened a
focused library of 502 natural compounds for their
potency to delay seed-mediated FAMAb42/Ab42
copolymerization. The compounds were added to
reactions at substoichiometric concentrations (2 mM)
to avoid unspecific effects through abnormal com-
pound aggregation, which is often observed at
higher concentrations [22].
Using this approach, we found that the natural
compounds, epigallocatechin gallate (EGCG),
wedelolactone (WED) and a-apo-oxytetracycline
(aOXY) potently delay the onset of seed-mediated
FAMAb42/Ab42 copolymerization in FP assays
(Fig. 1a and b), confirming previous results that
polyphenols and tetracyclines can slow down
amyloid fibrillogenesis [23,24]. Strikingly, an even
stronger effect on seed-mediated FAMAb42/Ab42 co-
aggregation was observed with the small molecule
sclerotiorin (SCL), a chlorine-containing azaphilone-
type natural product [25]. It was first isolated in 1940
from Penicillium sclerotiorum [26]. SCL has anti-
fungal activity [27] but also inhibits 5-lipoxygenase
activity and platelet aggregation [28]. An effect on
Ab42 aggregation in the context of AD, however, has
not been described.
The inhibitory effects of the compounds were
confirmed when they were added to FAMAb42/Ab42
co-aggregation reactions in the absence of pre-
formed seeds (Fig. 1c). Under these experimental
conditions, a substoichiometric concentration of the
compound SCL prevented the time-dependent
appearance of FP for 15 h, while in the presence
of the compounds EGCG, WED, or aOXY, FP
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2083Sclerotiorin Stabilizes Small Abeta42 Oligomersstarted to increase after ~8 h (Fig. 1c). Next, we
directly compared the potencies of the compounds
EGCG, WED, aOXY, and SCL in a time-resolved
Thioflavin T (ThT) aggregation assay [29]. In this
case, the compounds (10 mM) were incubated in the
presence and absence of preformed Ab42 seeds
(250 nM) with Ab42 monomers (25 mM) and ThT
(25 mM). Fibrillogenesis of Ab42 peptides was
monitored by quantification of ThT fluorescence
emission at 485 nm over time. We again observed
that SCL delays Ab42 polymerization more potently
than WED, aOXY, and EGCG (Fig. 1d and e),
confirming the results obtained with FP assays
(Fig. 1b and c).
Finally, we addressed the question of whether
SCL can influence the seeding activity of Ab
aggregates that are formed in the brains of AD
transgenic mice. In previous studies, fibrillar Ab
aggregates have been detected in the 5  FAD
mouse model [30]. Here, we isolated such structures
from APPPS1 mouse brain tissues [31]. Brain
extracts were first immunoprecipitated with beads
using the monoclonal anti-Ab antibody 6E10. Then,
the immunoprecipitates were released from the
beads by sonication and analyzed by SDS-PAGE
and immunoblotting, as well as staining of gels with
Coomassie blue R. We found that both high
molecular weight Ab aggregates and monomers
were very specifically enriched from mouse brain
extracts by the anti-Ab antibody 6E10 but not by the
isogenic control antibody (fig. S2a,b). Finally, the
enriched Ab structures were added as seeds to
fluorescently labeled and unlabeled Ab42 mono-
mers in FP assays. We observed that the immuno-
precipitated Ab aggregates prepared from APPPS1
transgenic mice are indeed seeding-competent
structures and potently decrease the lag phase in
FAMAb42/Ab42 co-aggregation reactions (Fig. 1f).
This effect, however, was diminished when SCL
(2 mM) was added to FP reactions together with the
immunoprecipitated Ab seeds. Based on the evi-
dence that SCL influences the seeding activity of Ab
aggregates enriched from AD transgenic mice, we
continued with a more detailed mechanistic investi-
gation of the compound.Fig. 1. Effects of small molecules on both spontaneous
assays. (a) Structures of the tested small molecules W
Epigallocatechin gallate (EGCG) and Sclerotiorin (SCL). (b,
and spontaneous (c) coaggregation of FAMAb42 (0.1 mM) and A
fibrillar assemblies (100 nM monomer equivalent) were adde
chemical compounds on seed-mediated (d) and spontaneous
(ThT, 25 mM) dye-binding assays. Preformed b-sheet-rich A
seeds. (f) SCL (2 mM) decreases the seeding activity of fib
transgenic mice in FP assays. Ab aggregates were immun
antibody. Coaggregation of FAMAb42 (0.1 mM) and Ab42 (1
polarization units (bef) Values are means ± SD, n ¼ 4.SCL slows fibrillogenesis by stabilizing small,
nonfibrillar Ab42 assemblies
To study how SCL influences amyloid aggregation,
we first analyzed the time-dependent formation of
FAMAb42/Ab42 co-assemblies in the presence and
absence of the compound (10 mM) by blue native (BN)
PAGEand immunoblotting. In the absence of SCL, we
observed a rapid increase of high-molecular-weight
Ab42 assemblies (HMWAs) in the gel pockets
(Fig. 2a), confirming previous observations that Ab42
peptides efficiently convert into high-molecular-weight
aggregates in cell-free assays [23]. Interestingly, the
formation of HMWAs was delayed for more than 10 h
in the presence of SCL, demonstrating that the
compound interferes with early events in the aggrega-
tion cascade and slows down the assembly of large
structures. Concomitantly with a decrease of HMWAs
in SCL-treated samples, however, an increase of
lower-molecular-weight Ab42 assemblies (LMWAs)
migrating at ~70e500 kDa was observed (Fig. 2a),
indicating that the compound stabilizes small Ab42
oligomers in the aggregation cascade. A similar result
was obtained when seeded Ab42 aggregation reac-
tions were treated with the chemical compound and
analyzed by BN-PAGE and immunoblotting (fig. S2c).
Next, we applied a native filter retardation assay
(nFRA) to assess the impact of SCL on the self-
assembly of Ab42 aggregates. With this method, the
formation of large, stable amyloid aggregates but not
monomers or small oligomers can be detected and
quantified in complex polymerization reactions [32].
We observed that upon SCL treatment (10 mM) the
time-dependent formation of large Ab42 aggregates
was delayed considerably (Fig. 2b and c), confirming
the results obtained by BN-PAGE and immunoblot-
ting (Fig. 2a).
We also studied the morphology of Ab42 aggre-
gates in SCL-treated and untreated reactions by
electron microscopy (EM). We treated Ab42 mono-
mers (10 mM) with preformed seeds (100 nM) and an
equimolar concentration of SCL and analyzed the
reactions after incubation for 15 h at 37 C. In
comparison to untreated samples, the abundance of
small spherical oligomers was increased in SCL-and seed-mediated Ab42 aggregation in FP and ThT
edelolactone (WED), a-apo-Oxytetracycline (a-OXY),
c) Effects of chemical compounds on seed-mediated (b)
b42 (10 mM) peptides in FP assays. Preformed b-sheet-rich
d as seeds. mP, milli-polarization units (d, e) Effects of
(e) aggregation of Ab42 (25 mM) peptides in Thioflavin T
b42 fibrils (250 nM monomer equivalent) were added as
rillar Ab aggregates prepared from the brains of 5xFAD
oprecipitated from mouse brain extracts using the 6E10
0 mM) peptides was monitored in FP assays. mP, milli-
Fig. 2. SCL slows down fibrillogenesis by stabilizing small, nonfibrillar Ab42 assemblies. (a) Analysis of SCL-
treated (10 mM) and untreated FAMAb42/Ab42 (0.1/10 mM) coaggregation reactions by blue native (BN) PAGE and
immunoblotting using the 6E10 antibody. (b) Detection of FAMAb42/Ab42 (0.1/10 mM) coaggregation by native filter
retardation assay (nFRA). SCL-treated (lower panel, 10 mM) and untreated reactions were analyzed. Aggregates retained
on filter membranes detected with 6E10 antibody. (c) Quantification of immunoreactive material on the filter membrane
shown in b. (d) Electron microscopy analysis of seeded (100 nM seeds) FAMAb42/Ab42 coaggregation reactions (0.1/
10 mM) in the absence and presence of SCL (10 mM) after 15 h. Seeds were prepared from synthetic Ab42 peptides (see
Fig. 1b). (e) Investigation of SCL-treated (lower panel, 10 mM) and untreated (upper panel) FAMAb42/Ab42 (0.1/10 mM)
coaggregation reactions by dot blot assays using the fibril-specific 352 antibody. (f) Quantification of immunoreactive
material shown in e. In b, c, e, and f, values are means ± SD, n ¼ 3. Asterisks indicate significant differences as
determined by the student t-test: * 0.05, ** 0.01, *** 0.001.
2084 Sclerotiorin Stabilizes Small Abeta42 Oligomerstreated reactions (Fig. 2d), substantiating the results
with BN-PAGE and immunoblotting that the com-
pound acts early in the aggregation cascade and
stabilizes small Ab42 assemblies. Similar results
were obtained when SCL-treated Ab42 aggregation
reactions in the presence of preformed seeds were
analyzed with AFM after 15 h (fig. S2d).
Finally, to quantify the formation of fibrillar Ab42
aggregates in SCL-treated and untreated reactions,
we performed dot blot assays using the monoclonalanti-Ab antibody 352. This antibody specifically
recognizes large ThT-reactive, fibrillar Ab42 aggre-
gates in dot blot assays, while unstructured mono-
mers and small oligomers are not detected (fig. S3a-
c). We found that, in comparison to controls, SCL
treatment efficiently delays the time-dependent
appearance of antibody 352 immunoreactivity in
Ab42 polymerization reactions (Fig. 2e and f),
confirming our observations by EM (Fig. 2d) that
the compound potently inhibits the formation of large
2085Sclerotiorin Stabilizes Small Abeta42 Oligomersfibrillar Ab42 aggregates. Together, this indicates
that SCL perturbs early events in the fibril assembly
process and kinetically stabilizes small Ab42 oligo-
mers prior to their conversion into large, fibrillar
structures.
SCL-stabilized Ab42 assemblies are structures
with low SDS stability and b-sheet content
For assessing the stability of the small SCL-
stabilized Ab42 assemblies, we analyzed the time-
dependent formation of amyloid aggregates in SCL-
treated (10 mM) and untreated reactions by SDS-
PAGE and immunoblotting. In untreated reactions,
SDS-stable HMWAs were predominantly detected
from ~4 h onward (Fig. 3a), indicating that in the
absence of the chemical compound, unstructured
Ab42 monomers rapidly self-assemble into large,
SDS-stable structures. However, SDS-stable
HMWAs were undetectable in SCL-treated reac-
tions. This indicates that the LMWAs and the
HMWAs observed in native gels in the presence of
SCL (Fig. 2a) are less stable structures, which
disassemble upon treatment with SDS into mono-
mers and very low molecular weight oligomers
(Fig. 3a). This result was confirmed when time-
resolved SCL-treated and untreated Ab42 aggrega-
tion reactions were systematically analyzed using a
denaturing filter retardation assay (dFRA), which
exclusively detects large, SDS- and heat-stable
Ab42 aggregates retained on filter membranes (fig.
S4a,b).
We next investigated the impact of SCL treatment
on the time-dependent formation of Ab42 assem-
blies by circular dichroism (CD) spectroscopy. With
this method, potential changes in the secondary
structure of spontaneously formed Ab42 aggregates
can be elucidated [17]. In comparison to untreated
controls (Fig. 3b), the b-sheet-content in SCL-treated
reactions was decreased (Fig. 3c), confirming our
hypothesis that the small compound-stabilized Ab42
structures (Fig. 2a) are structurally distinct from
typical, ordered amyloid fibrils with a high b-sheet
content [23].
A similar result was obtained when SCL-treated
and untreated Ab42 assemblies were analyzed with
the fluorescent dye ThT, which preferentially binds to
ordered amyloid fibrils with a high b-sheet-content
[33]. We treated Ab42 monomers (25 mM) with
increasing concentrations of SCL and incubated the
reactions for 15 h at 37 C in order to stimulate
aggregate formation. Then, the dye ThT (25 mM) was
added to reactions, and fluorescence emission was
quantified at 485 nm. In comparison to untreated
control reactions, we observed significantly
decreased ThT fluorescence in SCL-treated sam-
ples (fig. S5), supporting the hypothesis that the
compound-stabilized LMWAs in native gels (Fig. 2a)
are structures with low b-sheet content.Finally, we investigated whether SCL treatment
influences the binding of the fluorescent dye 8-
Anilino-1-naphthalene sulfonic acid (ANS) to spon-
taneously formed Ab42 assemblies. ANS was
previously shown to interact with fibrillar, b-sheet-
rich Ab42 aggregates [34], suggesting that SCL
treatment should decrease ANS fluorescence if it
prevents the formation of fibrillar structures. We
treated Ab42 monomers (20 mM) with an equal
concentration of SCL and incubated the reaction for
24 h at 37 C. Then, ANS was added, and emission
spectra between 380 and 650 nm were recorded
using a constant excitation wavelength of 350 nm.
A high emission peak with a maximum wavelength
of ~500 nm was detectable in untreated samples
(Fig. 3d), confirming the formation of fibrillar
Ab42 aggregates with solvent-exposed hydropho-
bic clusters. In comparison, ANS fluorescence
emission at ~500 nm was decreased in SCL-
treated samples, substantiating results obtained
with CD measurements (Fig. 3b and c) and
ThT-binding assays (fig. S5) that the compound
delays the formation of fibrillar, b-sheet-rich Ab42
aggregates.
SCL-stabilized Ab42 assemblies are nonseed-
ing-competent structures
Our studies indicate that SCL interferes with
very early steps in the Ab42 aggregation cascade
and leads to the stabilization of small structures
with low b-sheet content and a low propensity to
form fibrillar aggregates. This suggests that the
compound-stabilized Ab42 assemblies observed
in native gels (Fig. 2a) are structures with low
seeding activity. For addressing this question, we
first produced Ab42 assemblies in the presence
and absence of SCL. Ab42 monomers (10 mM)
were incubated with an equal concentration of
SCL for 18 h at 37 C in order to obtain higher
molecular weight aggregates. Then, these struc-
tures were added as seeds (100 nM) to FP-based
aggregation assays in 384-well microtiter plates to
monitor their seeding activity (fig. S6a). We
observed a significant shortening of the lag
phase, when Ab42 aggregates formed in the
absence of SCL were added to FAMAb42/Ab42
copolymerization assays (Fig. 3e and f), indicating
that spontaneously formed Ab42 aggregates
possess seeding activity. Strikingly, such an effect
was not observed when SCL-treated samples
were added to FP assays, demonstrating that
the small SCL-stabi l ized Ab42 oligomers
observed in native gels (Fig. 2a) are nonseeding-
competent structures. A similar result was
obtained when SCL-treated and untreated sam-
ples were added to a ThT-based Ab42 aggrega-
tion assay (fig. S6b), confirming the results
obtained with the FP assay.
Fig. 3. SCL-stabilized Ab42 assemblies are structures with low SDS stability and b-sheet content. (a) Analysis of
SCL-treated (10 mM) and untreated FAMAb42/Ab42 (0.1/10 mM) co-aggregation reactions by SDS-PAGE and
immunoblotting using the 6E10 antibody. (b,c) Investigation of spontaneous Ab42 (20 mM) aggregation in the absence
(b) and presence (c) of SCL (20 mM) by CD spectroscopy. (d) ANS dye-binding assay. Ab42 (20 mM) assemblies formed in
the presence (20 mM) or absence of SCL show distinct ANS-binding characteristics. (e) Effects of SCL-treated
(pAgg þ SCL) and untreated (pAgg) preformed Ab42 aggregates (100 nM monomer equivalents) on FAMAb42/Ab42 (0.1/
10 mM) coaggregation in FP assays. In control experiments, only SCL (0.2 mM) in the absence of preformed Ab42
aggregates were added to FP assays. mP, milli-polarization units (f) Calculated Dt50 values from aggregation curves
shown in e. Values are means ± SD, n ¼ 3 (b, c, d) and n ¼ 4 (e). Asterisks indicate significant differences as determined
by the student t-test: *** 0.001.
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soluble state
Our studies indicate that SCL slows down Ab42
fibrillogenesis because it interferes with very early
events in the aggregation cascade. We hypothe-
sized that SCL delays spontaneous aggregation by
binding directly to unstructured Ab42 peptides and
preventing their conformational conversion into b-
sheets. For addressing this question, we first
carried out binding studies with nuclear magnetic
resonance (NMR) techniques [35]. We treated
unstructured Ab42 monomers (50 mM) with a
substoichiometric concentration of SCL (10 mM)
and recorded 1H-NMR spectra after 22 h at 27 C.
We found that the resonances of the individual 1H
spectra of Ab42 peptides were sharp in compound
treated samples after 22 h, while they were
broadened in untreated samples (Fig. 4aed). This
indicates that the initially soluble Ab42 peptides
convert to insoluble, high-molecular-weight aggre-
gates in untreated samples (Fig. 4a,c), while they
remain soluble in SCL-treated reactions (Fig. 4b,d).
The relative peak intensities from selected signalsof methyl groups (Fig. 4a,b) were plotted over time
(Fig. 4e). We found that the relative peak intensities
decrease to ~20% after 11 h in untreated samples,
while they are only slightly reduced in compound-
treated samples. Together these experiments
indicate that SCL potently slows down Ab42
aggregation in vitro, although a stable compound-
peptide interaction cannot be detected in 1H NMR
measurements.
In a second experiment, we recorded two-dimen-
sional 1H and 15N spectra of treated and untreated
Ab42 samples after 24 h at 27 C. Using this
approach, we essentially confirmed that SCL treat-
ment prevents the broadening of resonances (fig.
S7a,b). Again, no major chemical shift perturbations
in the 1He15N-HSQC spectra were observed,
supporting our initial results.
Finally, we performed NMR WaterLOGSY
experiments to assess the interaction between
SCL and Ab42 peptides. This NMR technique is
more sensitive and commonly utilized to detect
interactions between polypeptides and small
molecules (<1 kDa) for fragment-based lead
discovery [36,37]. It allows the detection of
Fig. 4. SCL holds aggregation-prone Ab42 peptides in a soluble state. (a,b) Time-resolved 1H-NMR heat maps of
untreated (a) and SCL-treated (10 mM) (b) Ab42 (50 mM) aggregation reactions. (c,d) The first and last 1H-NMR spectrum
from the heat maps in a and b are shown; (e) Graphs show selected signals from the methyl group area (ppm, 0.91) of heat
maps in a and b. Black circles indicate Ab42 (50 mM) aggregation in the absence of SCL; red circles indicate SCL-treated
(10 mM) Ab42 aggregation reactions.
2087Sclerotiorin Stabilizes Small Abeta42 Oligomerscompound interactions without the need for 15N-
labeling of backbone amides. Ligand binding to
polypeptides is observed indirectly through the
nuclear Overhauser effect (NOE). In these NMR
experiments, the bulk water magnetization is
excited and transferred during the NOESY mixing
time to the bound ligand via different mechanisms
[38]. The 1D spectrum of SCL with characteristic
signals in the absence of Ab42 peptides is shown
in fig.S8a. The conversion of the peaks in the
control experiment (SCL only) indicates that the
compound does not self-aggregate in solution,
which may lead to false-positive interactions in the
presence of Ab42 peptides (fig. S8b). In the NMR
WaterLOGSY experiment with equal molar con-
centrations of SCL and Ab42 (50 mM), no NOE wasobserved, while in the range of 7.5e8.8 ppm the
characteristic Ab42 signals were detectable, indi-
cating that under these experimental conditions
the Ab42 peptides are soluble, but SCL binding
cannot be detected (fig. S8c). When a 10-fold
molar excess of SCL, however, was incubated with
Ab42 peptides, positive signals resulting from the
compound were detectable, indicating that SCL
indeed interacts with Ab42 molecules in solution.
Under these conditions, however, the typical Ab42
signals at 7.5e8.8 ppm were undetectable (fig.
S8d), indicating that the peptides form high
molecular structures at high concentrations of
SCL, which cannot be detected by 1D NMR
WaterLOGSY experiments. Together these results
indicate that SCL indeed weakly interacts with
2088 Sclerotiorin Stabilizes Small Abeta42 OligomersAb42 peptides in solution, promoting the assembly
of higher molecular weight structures.
SCL binds to Ab42 monomers and alters their
conformation
Our NMR WaterLOGSY experiments indicate that
SCL weakly interacts with Ab42 peptides, suggest-
ing that it might slow down fibrillogenesis because it
stabilizes their conformation in the nonaggregated
state. For addressing this question, we performed
ion mobility-mass spectrometry (IM-MS) experi-
ments, which enable the detection of Ab:drug
interactions, as well as of transient amyloidogenicFig. 5. SCL binding alters the conformation of Ab42
spectrometry (IM-MS) using nano-electrospray ionization. (a) M
spectrum of Ab42 (10 mM) in the presence of SCL (40 mM) in
spectrum of noncovalent þ4 charged (z/n ¼ þ4) 1:1 Ab42-S
[Ab42þSCL-18]4þ, magnification from b. Lower right panel, m
Ab42-SCL complex [Ab42þSCL]3þ and covalently bound SCL
spectrum of z/n¼þ3 charged Ab42 [Ab42]3þ species with calc
SCL [Ab42þSCL-18]3þ and (e) same species in noncovalentoligomers that are formed early in the aggregation
cascade [39]. IM-MS separates Ab42 peptide
species based on differences in their overall size,
as well as their charge [39]. It further provides an
absolute rotationally averaged collision-cross sec-
tion (CCS), which allows the prediction of secondary
structural changes within aggregating systems, such
as Ab42 [39e41]. We analyzed Ab42 monomers
(10 mM) in the presence (40 mM) and absence of SCL
after incubation for 2 h at 25 C by IM-MS. We readily
detected Ab42 monomers with a charge state of þ3
and þ 4 in both compound-treated and untreated
samples (Fig. 5a and b), confirming the previously
reported results [42]. Interestingly, we observed amonomers. Data were collected by ion mobility-mass
ass spectrum of Ab42 (10 mM) in 10 mM NH4Ac. (b) Mass
10 mM NH4Ac after 2 h at 25 C. Lower left panel, mass
CL complex [Ab42þSCL]4þ and covalently bound SCL
ass spectrum of noncovalent þ3 charged (z/n ¼ þ3) 1:1
[Ab42þSCL-18]3þ, magnification from b. (c) Ion mobility
ulated cross section, (d) same species covalently bound to
1:1 complex with SCL [Ab42þSCL]3þ.
2089Sclerotiorin Stabilizes Small Abeta42 Oligomersrelative increase of 3þ monomers in SCL-treated
samples, suggesting that SCL influences this Ab42
monomer population by a dynamic assembly-disas-
sembly process. This is further supported by addi-
tional changes at m/z ¼ 1625e1655 and m/
z ¼ 1220e1240 in compound-treated samples
(Fig. 5b), indicating that SCL binds either covalently
(e.g., [Ab42þSCL-18]3þ/4þ, due to water loss) or
noncovalently (e.g. [Ab42þSCL],3þ/4þ) to Ab42
monomers. Strikingly, IM-MS experiments further
showed that these compound interactions signifi-
cantly alter the conformation of Ab42 peptides.
Untreated samples showed a narrow, single popula-
tion of Ab42monomers with an averaged overall size
of 645 Å2, whereas the compound-treated samples
showed, independent of the binding mode (e.g.
covalent [Ab42þSCL-18] 3þ/4þ or noncovalent
[Ab42þSCL]3þ/4þ), an appearance of a second
Ab42 monomer population. The major conformation
of the SCL-bound species [Ab42þSCL]3þ (684 Å2)
showed a slight increase in size compared to the free
Ab42 monomers [Ab42] 3þ (645 Å2). This isFig. 6. SCL treatment leads to reduced cellular Ab42 agg
of cellular aggregate uptake experiments. pAGG, pre aggregat
of aggregates (fluorescent foci) in mammalian cells. (d) Qua
aggregation reactions with MTT assays. Aggregation reactions
Values are means ± SD, n ¼ 4 (d), 8 (b, c); Asterisks indicate
*  0.05, **  0.01, ***  0.001.expected due to ligand binding. However, a second
additional conformation appeared upon SCL binding
to the Ab42-monomer, which adopts a significantly
more compact structure (556 Å2) than the free
monomer. Such compact, unstructured conforma-
tions of Ab42 peptides were previously shown to be
less aggregation-prone [43,44] and to have a low b-
sheet content [45,46]. Together these studies
suggest that SCL binding leads to conformational
compaction at least in a small fraction of Ab42
monomers, which may influence their conversion
rate into aggregation-competent b-sheet-rich fibrils.
Neuroblastoma cells take up small SCL-stabi-
lized Ab42 assemblies less efficiently than
larger fibrillar aggregates
Recent studies indicate that b-sheet-rich, fibrillar
Ab42 aggregates are more easily taken up into
mammalian cells than unstructured monomers [47],
suggesting that small SCL-stabilized Ab42 assem-
blies might enter cells less efficiently than largerregate uptake and toxicity. (a) Schematic representation
ed material. (b, c) Quantification of number (b) and size (c)
ntification of toxicity of SCL-treated and untreated Ab42
were added after incubation for 24 h at 37 C to PC12 cells.
significant differences as determined by the student t-test:
2090 Sclerotiorin Stabilizes Small Abeta42 Oligomersstructures. To address this question, we first treated
a mix of TAMRA-labeled (1 mM) and unlabeled Ab42
peptides (20 mM) with SCL (20 and 40 mM) and
incubated this reaction for 18 h at 37 C to obtain
fluorescently labeled nonfibrillar SCL-stabilized
Ab42 assemblies (Fig. 6a). We confirmed by AFM
that the fibrillar TAMRAAb42/Ab42 co-aggregates are
morphologically very similar to Ab42 fibrils and that
the treatment of samples with SCL decreases the
spontaneous formation of large fibrillar structures in
vitro (fig. S9). Next, SH-EP neuroblastoma cells
were incubated for 5.5 h with the SCL-treated and
untreated fluorescently labeled Ab42 aggregate
species. Incubation for ~5 h was previously shown
to be sufficient for the uptake of a large fraction of
fibrillar Ab42 aggregates into SH-EP cells [47]. After
extensive washing to remove extracellular aggre-
gates, cells were transferred into a new microtiter
plate for image analysis. After further incubation for
2 h at 37 C, the number of TAMRA-labeled Ab42
puncta in cells was quantified by high-content
fluorescence imaging. Strikingly, we detected sig-
nificantly lower numbers of TAMRA-positive puncta
when cells were treated with small SCL-stabilized
structures rather than untreated Ab42 aggregates
(Fig. 6b), indicating that untreated fibrillar Ab42
aggregates are internalized much more efficiently
into mammalian cells than small SCL-stabilized
Ab42 oligomers (fig. S9). This result was confirmed
when the size of intracellular TAMRA-positive
puncta was quantified by automated fluorescence
microscopy (Fig. 6c).
SCL treatment decreases Ab42 aggregate toxi-
city in PC12 cells
Finally, we carried out standardized colorimetric 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) reduction assays [48] with
PC12 cells to assess the toxicity of SCL-treated
and untreated Ab42 aggregation reactions. We first
incubated Ab42 monomers for 22 h at 37 C with
different concentrations of SCL (1e200 mM). Then,
the Ab42 aggregation reactions were added to
PC12 cells, and cultures were incubated for 72 h at
37 C. Finally, MTT reduction was quantified in
PC12 cells using the established colorimetric assay
[48]. We found that b-sheet-rich fibrillar Ab42
aggregates (untreated samples) cause a pro-
nounced inhibition of MTT reduction (~40%,
Fig. 6d), confirming previously reported observations
that such structures are toxic and decrease the
metabolic activity of PC12 cells [23]. However,
inhibition of MTT reduction was diminished in a
concentration-dependent manner when SCL-treated
samples were analyzed, indicating that small com-
pound-stabilized oligomers (Fig. 2a,d) are less toxic
in MTT assays than large fibrillar, b-sheet-rich Ab42
aggregates. No inhibition of MTT reduction wasobserved when respective concentrations of SCL
were added to PC12 cells in the absence of Ab42
peptides (Fig. 6d).Discussion
The formation of large pathogenic, b-sheet-rich
Ab42 aggregates from natively unstructured mono-
mers is a complex multistep process involving the
assembly of various potentially proteotoxic aggre-
gate species, such as small oligomers, protofibrils, or
fibrils [6,9]. This suggests that an effective thera-
peutic strategy with small molecules should interfere
with very early steps in the aggregation cascade
before such toxic structures are formed. Compounds
may be found that maintain Ab42 monomers in their
native, unstructured state and thus hinder their
conversion into b-sheet-rich fibrillar aggregate spe-
cies. However, due to the fact that Ab42 monomers
in aqueous solutions are intrinsically unfolded
structures, the stabilization of their native state with
small-molecule binders is challenging [49].
In this study, we have identified the small molecule
sclerotiorin (SCL) that potently slows down both
seeded and nonseeded Ab42 fibrillogenesis in cell-
free assays (Fig. 1aef). SCL consists of a highly
oxygenated aromatic ring system and a nine-carbon
aliphatic diene side chain [25], suggesting that its
amphipathic properties are critical for its effects on
Ab42 aggregation. Amphipathic small molecules
and peptides have previously been identified as
enhancers and inhibitors of Ab42 and tau aggrega-
tion [50e52]. Their mechanisms of action, however,
remain largely unclear. Here, we provide experi-
mental evidence that at least a small fraction of
unstructured Ab42 peptides directly binds to the
chemical compound SCL (Fig. 5b and fig S8a-d),
suggesting that a weak compound interaction is
sufficient to slow down fibrillogenesis. Previous
investigations indicate that an interaction between
the small molecule 10058-F4 and unstructured MyC
peptides prevents their spontaneous assembly into
b-sheet-rich aggregates [53]. Furthermore, a large
number of reports indicate that the potent aggrega-
tion inhibitor EGCG [23] binds weakly to soluble,
unstructured aggregation-prone polypeptides, such
as Ab and a-synuclein, and decreases their propen-
sity to self-assemble into stable amyloid structures
[54,55].
Our data suggest that the interaction of SCL with
only a small fraction of aggregation-prone Ab42
molecules in a large population of unstructured Ab42
conformers is sufficient to efficiently slow down the
overall aggregate formation process (Fig. 1bef). The
spontaneous formation of stable, aggregation-com-
petent, b-sheet-rich Ab42 structures in a population
of unstructured molecules is a rare and energetically
unfavorable event [11,56]. Thus, compounds that
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which occurs very early in the aggregation cascade,
should be active at substoichiometric concentrations
in vitro and in vivo.
We gained experimental evidence that SCL
weakly interacts with aggregation-prone Ab42 pep-
tides in solution (fig. S8a-d). We suggest that it may
directly associate with the central or the C-terminal
hydrophobic regions in Ab42 peptides [57], which
facilitate b-sheet formation and promote the inter-
molecular association of monomers [58]. This may
involve the hydrophobic diene side chain in the small
molecule (Fig. 1a). However, the oxygenated bicyc-
lic ring system in SCL may also be critical for
targeting aggregation-prone Ab42 peptides. It may
form covalent bonds with polar amino acids in the
Ab42 peptide, such as Lys 16 or Lys28 that are
important for the formation of a stable, aggregation-
competent b-hairpin structure [58]. Our IM-MS
experiments confirm this view and indicate that at
least a small fraction of Ab42 monomers covalently
interact with SCL (Fig. 5aec). Preliminary investiga-
tions of the SCL:Ab42 complex with higher-energy
C-trap dissociation experiments (unpublished
results) also support this hypothesis. However,
further studies are necessary to substantiate these
initial results.
We suggest that the SCL interaction affects the
conformational space of aggregation-prone, disor-
dered Ab42 peptides, and stabilizes the formation of
aggregation-incompetent, small oligomers prior to
the formation of fibrillar aggregates [49]. Recent
biochemical and biophysical investigations support
our hypothesis that aliphatic structures can directly
target aggregation-prone Ab40 peptides and prevent
their assembly into amyloid aggregates in vitro [59].
Our studies indicate that SCL, even at very low
concentrations, converts unstructured Ab42 mono-
mers into small, seeding-incompetent, spherical
oligomers with a low aggregation-propensity
(Figs. 2 and 3). Similar structures have previously
been obtained when aggregation-prone unstruc-
tured a-synuclein and Ab42 polypeptides were
treated with the polyphenol EGCG [23]. However,
our investigations revealed that the SCL-stabilized
oligomers readily dissociate into monomers upon
SDS treatment (Fig. 3a), while this is not the case in
the presence of EGCG [23]. This demonstrates that
the SCL- and EGCG-generated oligomers are
distinct in terms of their biochemical properties. We
suggest that EGCG stabilizes Ab42 oligomers
because it cross-links unstructured polypeptides
[60]. However, such a mechanism of action most
likely is not operational with SCL. Our MS-based
investigations (Fig. 5b) indicate that the Ab42
peptides are not cross-linked upon SCL treatment.
Under the experimental conditions used, only stable
interactions between Ab42 monomers and SCLmolecules were readily observed. We suggest that
SCL promotes the intermolecular association of
monomers due to its amphipathic properties [25],
leading to the formation of relatively small, unstable
Ab42 oligomers (Fig. 2a). A similar mechanism of
action was previously described for the small-
molecule aggregation inhibitor FN075 that triggers
both CsgA and a-synuclein oligomer formation [61].
Experimental evidence has been provided that a
large number of fibrillar but also nonfibrillar aggre-
gate assemblies with b-sheet-rich domains cause
dysfunction and toxicity in cell-based assays
[23,62,63]. This suggests that stable b-sheets in
aggregate assemblies are important molecular
determinants of cellular toxicity. Our investigations
with PC12 cells and SCL-treated and untreated
aggregation reactions support these observations.
We found that in comparison to untreated reactions,
inhibition of MTT reduction was significantly
decreased in SCL-treated samples (Fig. 6d), sug-
gesting that b-sheet-rich fibrillar rather than unstruc-
tured nonfibr i l lar Ab42 assemblies cause
dysfunction and toxicity in cells. This result is also
supported by our observations that fibrillar Ab42
assemblies are taken up into cells much more
efficiently than nonfibrillar structures (Fig. 6b and
c). Recent investigations indicate that intraneuronal
Ab structures cause dysfunction and drive patho-
genesis in AD [64], suggesting that the uptake of Ab
aggregates is a prerequisite for the induction of
toxicity in PC12 cells. Our results agree with
previous observations that fibrillar Ab42 assemblies
are internalized into neuronal cells much more
efficiently than nonfibrillar structures [47]. Further-
more, they substantiate investigations indicating that
b-sheet-rich Ab assemblies expose unique hydro-
phobic surfaces and efficiently disrupt membranes in
cell-free assays [63]. Finally, they confirm the
hypothesis that small, seeding-competent fibrillar
amyloid assemblies are disease-relevant species
with high cellular toxicity [8,23,65e67].
Overall, our study suggests that compounds
targeting and stabilizing small unstructured Ab42
oligomers with low b-sheet content could be useful
for therapy development. Stabilizing of folded
transthyretin (TTR) tetramers with the small mole-
cule tafamidis has been shown to be effective for the
treatment of familial amyloid polyneuropathy (FAP),
a disease associated with the misfolding and
aggregation of the protein TTR [19]. We hypothesize
that drug combinations targeting different individual
microscopic steps in the amyloid aggregation
cascade may be an effective therapeutic strategy
for the treatment of AD. Besides compounds that
stabilize unstructured Ab42 oligomers and thereby
slow down primary and secondary nucleation steps
[68], compounds that target and disrupt more
mature b-sheet-rich amyloid structures may also
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has recently been described to successfully
decrease plaque pathology, aggregate-related
inflammatory expression changes, and disease
symptoms in a transgenic AD model [21]. On the
basis of the mechanistic studies presented here, we
conclude that SCL or compounds with a similar
mode of action may have considerable potential as
drug candidates for the treatment of AD. Previously,
related azaphilone compounds from fungi have
been described as modulators of tau aggregation
in vitro [52].Materials and Methods
Ab42 peptide stock solutions
Synthetic Ab1-42 (Ab42) was purchased from Bachem
(Bubendorf, Switzerland, #H-1368) and dissolved in
1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) to 5 mg/ml, vor-
texed for 1 min and sonicated for 10 min (ultrasonic bath,
SONOREX DIGITEC, Bandelin, Berlin Germany) at 4 C.
The solution was incubated 3 times at 22 C for 1 h,
vortexed for 1 min, sonicated for 1 min, stored for 67 h at
22 C, aliquoted and lyophilized (RVC 2e25 CDplus, Christ,
Osterode am Harz, Germany). Monomeric Ab42 solutions
were prepared from the aliquots by dissolving the peptide in
10 mM NaOH to 200 mM, followed by 1 min vortexing and
5 min sonication. Aggregation reactions were started by
mixing 200 mM Ab42 peptide stock solutions with low salt
buffer (LSB: 10mMKH2PO4, 10mMK2HPO4, 10 mMNaCl,
pH 7.4) to obtain final peptide concentrations. All concen-
trations of fibrillar Ab42 species refer to the equivalent
concentration of Ab42 monomers.
Fibrillar Ab42 seeds
Synthetic Ab1-42 (Ab42) peptides produced by the
laboratory of Dr. Volkmer-Engert (Institute for Medical
Immunology, Charite - Universit€atsmedizin Berlin, Ger-
many) were dissolved in HFIP, vortexed for 1 min followed
by incubation for 1 h at 20 C (four times) and sonication
(ultrasonic bath, SONOREX DIGITEC, Bandelin, Berlin
Germany) for 10 min. After additional incubation of 16 h at
20 C and 30 min sonication, the solution was aliquoted,
frozen in liquid nitrogen, lyophilized with a vacuum
concentrator RVC 2e25 CDplus (Christ, Osterode am
Harz, Germany), and stored at 20C. For the preparation of
fibrillar assemblies (FAs), aliquots were dissolved in
100 mM NaOH to 10 mg/ml; vortexed for 1 min, sonicated
for 5 min, dissolved with a low salt buffer to 200 mM and
incubated for 6 h at 37 C at 300 rpm. Aliquots were stored
at 80C.Fluorescence polarization-based Ab42 aggregation
assay
Carboxyfluorescein labeled b-amyloid [1e42] peptides
(Anaspec, Fremont, USA, #AS-23525) were dissolved in1 mM NaOH to 50 mM and stored as a stock solution.
0.1 mM of this tracer together with 10 mM Ab42 mono-
mers in LSB were combined with 40 nM Ab42 FAs
(seeds) and test compounds (1 mM). The aggregation
mixtures were replenished with LSB to a total volume of
40 ml. The fluorescence polarization measurements were
carried out for a minimum of 16 h with a single
measurement every 15 min at 37 C in a plate reader
(Infinite M1000/Infinite M1000 PRO, Tecan, M€annedorf,
Switzerland) at an excitation wavelength of 470 ± 5 nm
and an emission wavelength of 528 ± 20 nm in 384-well
plates with 5 s shaking before each reading. Values are
means of five technical replicates. Polarization values
are expressed as dimensionless mP values, calculated
by the plate-reader software i-control (Tecan,
M€annedorf, Switzerland).
Preparation of Ab seeds from mouse brains
Frozen tissue was weighed and homogenized in a 5-
fold excess (w/v) of ice-cold 50 mM Tris-HCl pH 7.5,
150 mM NaCl, 0.1% SDS, 0.5% Sodium deoxycholate,
1% Triton X-100, 0.25 U/ml Benzonase and a complete
protease inhibitor cocktail using a schuett homgenplus
(schuett-biotec GmbH, Goettingen, Germany) semi-auto-
matic homogenizer (700 rpm). The homogenate was
centrifuged for 20 min at 1500g at 4 C to remove cell
debris. The supernatant was transferred to a new tube,
and the total protein concentration was determined with
the Pierce BCA assay (ThermoFisher Scientific/Life
Technologies GmbH, Darmstadt, Germany) using BSA
as a standard. Seeding-competent Ab aggregate species
were enriched from mouse brain homogenates (prepared
from 0.25 mg brain tissue of APPPS1 transgenic mice)
through immunoprecipitation with magnetic protein G
beads (Pierce™ Protein G Magnetic Beads, Thermo-
Fisher Scientific/Life Technologies GmbH, Darmstadt,
Germany) coated with 6E10 antibody. Antibody bound
beads were incubated with homogenate at room tem-
perature for 30 min. Beads were then washed three times
in LSB before being subjected to sonification for 30 s
(Model 120 Sonic Dismembrator, Fisher Scientific GmbH,
Schwerte, Germany). Ab aggregate species (10 ml)
released from beads by sonication were used as
seeding-competent material in FP assays.
Biochemical characterization of Ab42 assemblies in
FP assays
Co-aggregation of Ab42 (10 mM) and FAMAb42
(0.05 mM) in the presence (2 or 10 mM) and absence of
chemical compounds was monitored in a time-dependent
manner by quantification of FP. The impact of seeds on
spontaneous FAMAb42/Ab42 co-aggregation was
assessed by the addition of preformed Ab42 fibrils
(100 nM) to reactions. After 4, 8, 12, 14, and 24 h, the
FP measurements were interrupted, and samples were
taken from the microtiter plate and stored on ice. Finally,
compound-treated and untreated FAMAb42/Ab42 coaggre-
gates were analyzed by SDS- or BN-PAGE followed by
immunoblotting. In addition, FAMAb42/Ab42 aggregate
species were assessed by AFM, EM, dot blot, or filter
assays.
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Sclerotiorin (SCL, # 89460, Cayman Chemicals, Ann
Arbor, USA,  98% or # AG-CN2-0054, AdipoGen Life
Services, San Diego, USA, SCL  97%), Epigallocatechin
gallate (EGCG, # 93894, Sigma-Aldrich/Merck (Germany,
 95%), Wedelolactone (WED, #W4016, Sigma-Aldrich/
Merck (Germany,  98%), a-apo-Oxytetracycline (a-OXY,
# A1220000, Sigma-Aldrich (Germany,  98%).
Antibodies
Commercially available antibodies applied in this study
are anti-b-amyloid 1e16 antibody (clone 6E10, Biolegend,
USA) and anti-mouse IgG and peroxidase-conjugated
IgGs for immunoblots (Sigma-Aldrich/Merck, Munich,
Germany). The fibril-specific monoclonal anti-b-amyloid
antibody 352 [21] is commercially available at Synaptic
Systems GmbH (Goettingen, Germany).
Thioflavin T assay
The aggregation of HFIP treated Ab42 peptides (25 mM)
was monitored over time with Thioflavin T (ThT, 25 mM) in
the presence or absence of chemical compounds. For
stimulating aggregation preformed short Ab42 fibrils
(250 nM) were added as seeds to reactions. ThT
fluorescence was measured in LSB over 16 h at 37 C.
ThT fluorescence was recorded using a plate reader
(Infinite M200, Tecan, M€annedorf, Switzerland) with
15 min reading intervals and 5 s shaking before each
read using an excitation wavelength of 420 ± 9 nm and an
emission wavelength of 485 ± 20 nm.
Seeding activity of SCL-treated and untreated Ab42
aggregation reactions
Ab42 monomers (10 mM) were incubated for 18 h at
37 C in the presence and absence of SCL (10 mM). Then,
the generated Ab42 assemblies (250 or 100 nM) were
added as seeds to ThT- (25 mMAb42, 25 mM ThT) and FP-
based (10 mM Ab42, 0.05 mM tracer) aggregation assays,
respectively. In the control experiments, respective SCL
concentrations (250 or 100 nM) were added to ThT and FP
reactions in the absence of preformed Ab42 assemblies.
ANS assay
Ab42 peptides (20 mM) were incubated without or with
20 mM SCL for 24 h. Then, 8-Anilino-1-naphthalene
sulfonic acid ammonium salt (ANS, 100 mM; # A1028
Sigma-Aldrich, Germany) was added to reactions, and
fluorescence spectra were measured with an excitation
wavelength of 350 nm ± 10 nm and an emission between
380 nm ± 20 nm and 650 nm ± 20 nm using a plate reader
(Infinite M200, Tecan, M€annedorf, Switzerland).
Analysis of Ab42 assemblies by SDS- and BN-PAGE
followed by immunoblotting
Samples from Ab42 aggregation reactions (4.5 ml,
10 mM) were mixed with 2.5 ml of NuPAGE LDS samplebuffer (ThermoFisher Scientific, Germany), 2.9 ml LSB
buffer and 0.1 ml 5 M DTT and boiled for 5 min at 96 C
before they were loaded onto a NuPAGE Bis-Tris 4e12%
gel (ThermoFisher Scientific, Germany). SDS-PAGE
analysis was performed without DTT and heated denatur-
ing. For the investigation of Ab42 aggregates under
nondenaturing conditions Novex Bis-Tris 4e16% gels
(ThermoFisher Scientific, Germany) were used. 4.5 ml of
Ab42 samples (10 mM), 2.5 ml of NativePAGE 4  Sample
Buffer (ThermoFisher Scientific, Germany) and 3 ml LSB
buffer were loaded in each well. Separation of Ab42
assemblies on SDS or native gels was performed
according to standard protocols. Ab42 peptides retained
on membranes were visualized by immunoblotting using
the 6E10 antibody.
Atomic force microscopy
20 ml of spontaneously formed Ab42 aggregates (10 mM)
were added onto a freshly cleaved sheet mica (Nanoworld,
Switzerland), which was glued on a microscope slide and
incubated for 10 min. The solution was removed with a lint-
free cloth and washed 4  with Milli-Q H2O. The samples
were dried, and AFM images were recorded on a
Nanowizard II/Zeiss Axiovert setup (JPK, Germany)
using an intermittent contact mode and FEBS cantilevers
(Veeco, USA).
Dot blot assay
Samples with Ab42 monomers or aggregates (50 and
100 ng) were filtered through nitrocellulose membranes
(0.45 mm; GE Healthcare Life Sciences, Germany).
Membranes were then blocked for 30 min with 3% skim
milk in PBS containing 0.05% Tween. After washing,
membranes were incubated with the sequence-specific
anti-Ab antibody 6E10 (dissolved 1:1000 in PBS with 3%
skim milk containing 0.05% Tween) overnight, washed
with PBS (0.05% Tween) and incubated with a horseradish
peroxidase-conjugated secondary antibody (Promega,
Germany) for 1 h. Membranes were developed with
ChemiGlow West Chemiluminescence Substrate (Alpha
Innotech, USA), and chemiluminescence was measured
with FujiFilm LAS-3000 (Fuji Photo Film (Europe) GmbH,
Germany. Dot blots were quantified using the AIDA Image
Analyzer software (Raytest, Germany).
Filter retardation assay
In denaturing filter retardation assays (dFRAs), Ab42
aggregates (200 or 400 ng) were monitored after adding
an equal volume of 4% sodium dodecyl sulfate (SDS) and
100 mM dithiothreitol (DTT) to reactions. Samples were
boiled at 98 C for 5 min before filtering them through a
cellulose acetate membrane with a pore size of
~0.2 mm (GE Healthcare Life Sciences, Germany). For
analysis of Ab42 aggregates under nondenaturing condi-
tions in a native filter retardation assay (nFRA), Ab42
aggregation reactions (200 or 400 ng) were filtered through
a cellulose acetate membrane without SDS and DTT
treatment. Membranes were blocked for 30 min with 3%
skim milk in PBS containing 0.05% Tween and aggregates
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immunoblotting.
MTT assay
For assessing the toxicity of Ab42 assemblies formed in
the presence (1, 20, 50, 100, 200 mM) or absence of SCL,
HFIP treated Ab42 peptides were dissolved to 200 mM in
10 mM NaOH and immediately diluted with SCL in LSB to
15 mM. Then, the samples were incubated for 24 h at 37 C
and 300 rpm in an Eppendorf shaker. 10 ml of these
aggregation reactions were mixed with 90 ml medium and
added to PC12 cells (20,000 cells/well in a 96 well
microtiter plate; Greiner Bio-ONE, no. 655,180, Germany).
Cells with SCL-treated and untreated aggregation reac-
tions were incubated for 72 h at 37 C. MTT reagent (15 ml,
Promega GmbH, CellTiter 96® Nonradioactive Cell Pro-
liferation Assay, Mannheim, Germany) was added to each
well. Then, after an incubation of 4 h the color reaction was
quenched by adding stop solution (100 ml). Samples were
incubated for 1 h. The absorption was measured in a plate
reader (Infinite M200, Tecan, M€annedorf, Switzerland).
Values were calculated as % DMSO control (mean ± SD,
n ¼ 3e5 technical replicates; all experiments were
repeated 3 times with very similar results). As a positive
control, cells were treated with 50 mM cycloheximide. Also,
corresponding SCL concentrations without Ab42 aggre-
gates were analyzed.
Uptake of Ab42 aggregates into mammalian cells
HFIP treated Ab42 peptides were dissolved to 200 mM in
10 mM NaOH and immediately diluted with TAMRA-
labelled Ab42 peptides (TAMRAAb42, 50 mM in 10 mM
NaOH) in LSB to obtain a concentration of 20 mM. The final
concentration of TAMRA-labelled Ab42 peptides in this
solution was 5%. Then, the mixture of TAMRAAb42/Ab42
peptides was aggregated in the presence (20, 40 mM) and
absence of SCL for 18 h. Finally, the generated
TAMRAAb42/Ab42 coassemblies were sonicated (Model
120 Sonic Dismembrator, Fisher Scientific GmbH,
Schwerte, Germany) 6-times for 10 s on ice.
Preformed compound-treated and untreated
TAMRAAb42/Ab42 co-assemblies (600 nM) were added
to SH-EP cells (900,000 cells/well, in a 6-well plate
cultured for 1 day in DMEM, 31885-049, Life Technol-
ogies, US) and incubated for 5.5 h. Then, the cells were
washed with 2 ml PBS, trypsinized (0.5 ml), centrifuged,
and resuspended in 2 ml cell medium. The cell number
was adjusted (450,000 cells per ml), and 80 ml of the
suspension was incubated for 2 h with 80 ml cell medium
in a 96-well microtiter plate. The cell nuclei were stained
with Hoechst 33342 (1:2500 dilution of bis-Benzimide H
33342 trihydrochloride, Sigma-Aldrich/Merck, Munich,
Germany). Finally, cells were fixed with a final concen-
tration of 2% formaldehyde and washed 2 times with
PDS (200 ml). The number of cells, as well as the
number and sizes of TAMRAAb42/Ab42 co-aggregates in
cells, were quantified using the Cellomics technology
(mean ± SD, n ¼ 10e15 technical replicates; all
experiments were independently repeated 2 times with
very similar results).Solution NMR
Samples were prepared by mixing 40 ml of Ab42
peptides in 10 mM NaOH with 530 ml LS buffer.
Subsequently, 30 ml DMSO-d6 were added, either pure
DMSO-d6 or a stock solution of SCL in DMSO-d6 (1 mM or
200 mM to yield concentrations of 10 or 50 mM, respec-
tively). The solutions were then transferred into a 5 mm
sample tube and inserted into the magnet. After mixing the
solutions, the NMR experiments were started after 5 or
10 min. The resulting 5% of DMSO-d6 were used for the
lock during the experiments. Experiments were performed
at 280 or 300 K on an AVeIIIe600 NMR-spectrometer
(600 MHz 1H frequency, Bruker Biospin, Karlsruhe,
Germany) equipped with a TCI cryoprobe with one-axis
self-shielded gradients. Temperatures were calibrated
using d4-methanol. Topspin 3.2 was used to control the
spectrometer. One-dimensional NMR experiments were
performed using 3-9-19 WATERGATE [69] water suppres-
sion implemented in an excitation sculpting sequence [70]
and recording 4096 complex points (acquisition time 409.6
msec), a relaxation delay of 1.3 s and 128 scans. Decay
curves were recorded using the same pulse sequence in a
pseudo-2D experiment with 350 FIDs, covering a time of
22 h. Two-dimensional, 1H,15N-correlations were per-
formed either as HSQC experiments [71] or as SOFAST-
HMQC [72] experiments. 512(1H)*128(15N) complex
points were acquired, with tH,max¼ 51.2 ms, tN,max¼ 64 ms
and 64 scans. WaterLOGSY experiments were performed
using reported information from the literature [73] and
recording 4096 complex points (acquisition time 409.6
msec), a relaxation delay of 1.3 s, an exchange delay of
2.3 s, a trim pulse of 30 msec and 128 scans. NMR data
were processed, and spectra viewed using topspin 3.2
(Bruker Biospin, Karlsruhe, Germany). The resonance
assignment of the 1H,15N-correlation was transferred from
Roche et al. [74].
IM-MS measurements
Linear drift tube (DT) IM-MS measurements were
performed on a modified Synapt G2-S HDMS (Waters
Corporation, Manchester, UK) described in detail else-
where [75]. Prior to IM-MS measurements the freeze-
dried aliquot of the Ab42 peptides was diluted to obtain a
10 mM concentrated solution either in a) 10 mM ammo-
nium acetate buffer þ0.1% (v/v) DMSO or in b) 10 mM
ammonium acetate buffer þ 0.1% (v/v) DMSO containing
40 mM SCL. For nano-electrospray ionization (nano-ESI),
typically, 5 ml of the sample was loaded and electro-
sprayed by applying 1.1 kV capillary voltage. Further
parameters were: 30 V sampling cone voltage, 30 V
source offset voltage, 30 C source temperature, 0 V trap
CE, 0 V transfer CE, 2 ml/min trap gas flow. Ion mobility
parameters were: 2.2 Torr helium IMS gas, 27 C IMS
temperature, 5.0 V trap DC entrance voltage, 6.0 V trap
DC bias voltage, 5.0 V trap DC voltage, 1.0 V trap DC
exit voltage, 25.0 V IMS DC entrance voltage,
70e110 V helium cell DC voltage, 40.0 V helium exit
voltage, 70e100 V IMS bias voltage, 0 V IMS DC exit
voltage, 5.0 V transfer DC entrance voltage, 15.0 V
transfer DC exit voltage, 150 m/s trap wave velocity,
2.0 V trap wave height voltage, 150 m/s transfer wave
2095Sclerotiorin Stabilizes Small Abeta42 Oligomersvelocity, 2.0 V transfer wave height voltage. IM-MS
spectra were recorded in the positive ion mode, and
drift times were converted to rotationally-averaged colli-
sion cross-sections (CCS) using the Mason-Schamp
equation [76].General
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